Osr Health Inc

This management proposal requests a non-binding advisory approval of the Company’s disclosed named executive officer compensation (the say-on-pay vote). Management is seeking shareholder input to affirm its compensation philosophy and to provide the Board and Compensation Committee with feedback that they will consider in future decisions; although advisory, the vote is intended to signal stockholder support or concern and inform compensation governance. The proxy describes compensation as designed to attract and retain executives and to balance responsible pay practices with incentives for value creation, noting the company’s emerging growth company status and related exemptions from some disclosure and governance requirements. The Compensation Committee and Board emphasize that outcomes will be considered when making future compensation decisions, reflecting a responsiveness to investor sentiment. Because the vote is advisory, it will not be binding on the Board, nor will it create fiduciary obligations, but a negative vote could prompt changes to pay practices, disclosure, or governance. The proposal should be evaluated in light of the named executive officers’ disclosed salaries, lack of equity awards granted during recent years, the existence of the 2025 Omnibus Incentive Plan and available share reserve, and the company’s aims to use equity awards for retention and alignment. Given the Board’s recommendation and stated rationale, the management position is that the current mix of cash and potential equity awards strikes the appropriate balance, but investors should weigh pay levels and structures against company performance, stage, and governance norms. The outcome will be a key signal to the Compensation Committee about whether current pay practices align with investor expectations, particularly as the company contemplates future equity grants under the Omnibus Plan.

This management proposal asks shareholders to approve an amendment to the Company’s Certificate of Incorporation to increase authorized common shares from 100 million to 250 million. Management frames the increase principally to provide capacity for a proposed shareholder loyalty program that could issue additional shares to long-term holders if specified price and holding period thresholds are met, and secondarily to preserve flexibility for equity or equity-linked financings, strategic transactions (including mergers and acquisitions), and general corporate purposes such as equity compensation and satisfying obligations under outstanding securities. The Board emphasizes that the amendment will not change par value or the rights of existing shares, but notes that future issuances could dilute existing stockholders’ voting power and economic interests and could be used in ways that have anti-takeover implications; it states the proposal is not being made in response to any known takeover effort. The Board intends to file a Certificate of Amendment promptly upon approval and notes that the loyalty program and certain issuances may require additional approvals, a registration statement, and Nasdaq compliance. Investors should consider the breadth of discretion that additional authorized shares would give the Board, the potential dilutive effects depending on future issuances, and the trade-off between strategic flexibility and shareholder dilution. The recommendation to approve is supported by the Board’s view that constrained authorized shares would impede the company’s ability to execute financings, pursue transactions, and implement the proposed loyalty program without delay or additional shareholder votes. Given the company’s capital needs and strategic objectives as described, a vote for approval supports management’s stated aim to maintain optionality, while a vote against would constrain near-term equity-based strategic options and could require the company to seek frequent further shareholder approvals.